Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population
Cytochrome P450 2A6 (CYP2A6) is involved in the C-oxidation of nicotine and in the metabolic activation of tobacco nitrosamines. Recent data have suggested that CYP2A6 genetic polymorphisms might play a role in tobacco dependence and consumption as well as in lung cancer risk. However, the previousl...
Gespeichert in:
| Veröffentlicht in: | Pharmacogenetics (London) 2001-02, Vol.11 (1), p.39-44 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 44 |
|---|---|
| container_issue | 1 |
| container_start_page | 39 |
| container_title | Pharmacogenetics (London) |
| container_volume | 11 |
| creator | LORIOT, Marie-Anne REBUISSOU, Sandra OSCARSON, Mikael CENEE, Sylvie MIYAMOTO, Masami ARIYOSHI, Noritaka KAMATAKI, Tetsuya HEMON, Denis BEAUNE, Philippe STÜCKER, Isabelle |
| description | Cytochrome P450 2A6 (CYP2A6) is involved in the C-oxidation of nicotine and in the metabolic activation of tobacco nitrosamines. Recent data have suggested that CYP2A6 genetic polymorphisms might play a role in tobacco dependence and consumption as well as in lung cancer risk. However, the previously published studies were based on a genotyping method that overestimated the frequencies of deficient alleles, leading to misclassification for the CYP2A6 genotype. In this study, we genotyped DNA from 244 lung cancer patients and from 250 control subjects for CYP2A6 (wild-type allele CYP2A6*1, and two deficient alleles: CYP2A6*2, and CYP2A6*4, the latter corresponding to a deletion of the gene) using a more specific procedure. In this Caucasian population, we found neither a relation between genetically impaired nicotine metabolism and cigarette consumption, nor any modification of lung cancer risk related to the presence of defective CYP2A6 alleles (odds ratio = 1.1, 95% confidence interval = 0.7-1.9). |
| doi_str_mv | 10.1097/00008571-200102000-00005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_599007</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70572436</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-bb17d86804b601bfe080e0ca93e928ff32e14bdce5c51eb0a6f03d4ba20d60193</originalsourceid><addsrcrecordid>eNo90E1PxCAQBmAOGtevv2BITLxVByhtOZqNX8kmetDEWwN06nZtoUIbs_9ezK5yADLzzHsYQiiDawaqvIF0KlmyjAMwSBdkvyV5QI5BFZAJlr8vyEmMm9SXQvAjsmCMQwlcHZPNAzqcOktH328HH8Z1F4dIfUvtdvJ2HfyA9CWXQPltQTtHNbU6Yma9m4LvaZzmZku9o_3sPlLLWQw7dh_Q2XXKHedeT513Z-Sw1X3E8_17St7u716Xj9nq-eFpebvKbJ4XU2YMK5uqqCA3BTDTIlSAYLUSqHjVtoIjy01jUVrJ0IAuWhBNbjSHJg0ocUqyXW78xnE29Ri6QYdt7XVX70uf6Ye1VAqgTP5q58fgv2aMUz100WLfa4d-jnUJsuS5KBK82MPZDNj8B_9tM4HLPdDR6r4NaR1d_HcKkpTiB-uQg0Y</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70572436</pqid></control><display><type>article</type><title>Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population</title><source>Journals@Ovid Ovid Autoload</source><source>MEDLINE</source><creator>LORIOT, Marie-Anne ; REBUISSOU, Sandra ; OSCARSON, Mikael ; CENEE, Sylvie ; MIYAMOTO, Masami ; ARIYOSHI, Noritaka ; KAMATAKI, Tetsuya ; HEMON, Denis ; BEAUNE, Philippe ; STÜCKER, Isabelle</creator><creatorcontrib>LORIOT, Marie-Anne ; REBUISSOU, Sandra ; OSCARSON, Mikael ; CENEE, Sylvie ; MIYAMOTO, Masami ; ARIYOSHI, Noritaka ; KAMATAKI, Tetsuya ; HEMON, Denis ; BEAUNE, Philippe ; STÜCKER, Isabelle</creatorcontrib><description>Cytochrome P450 2A6 (CYP2A6) is involved in the C-oxidation of nicotine and in the metabolic activation of tobacco nitrosamines. Recent data have suggested that CYP2A6 genetic polymorphisms might play a role in tobacco dependence and consumption as well as in lung cancer risk. However, the previously published studies were based on a genotyping method that overestimated the frequencies of deficient alleles, leading to misclassification for the CYP2A6 genotype. In this study, we genotyped DNA from 244 lung cancer patients and from 250 control subjects for CYP2A6 (wild-type allele CYP2A6*1, and two deficient alleles: CYP2A6*2, and CYP2A6*4, the latter corresponding to a deletion of the gene) using a more specific procedure. In this Caucasian population, we found neither a relation between genetically impaired nicotine metabolism and cigarette consumption, nor any modification of lung cancer risk related to the presence of defective CYP2A6 alleles (odds ratio = 1.1, 95% confidence interval = 0.7-1.9).</description><identifier>ISSN: 0960-314X</identifier><identifier>DOI: 10.1097/00008571-200102000-00005</identifier><identifier>PMID: 11207029</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams and Wilkins</publisher><subject>Aryl Hydrocarbon Hydroxylases ; Biological and medical sciences ; Case-Control Studies ; Cytochrome P-450 CYP2A6 ; Cytochrome P-450 Enzyme System - genetics ; DNA Ligases - genetics ; France - epidemiology ; Fundamental and applied biological sciences. Psychology ; General pharmacology ; Genetic Predisposition to Disease ; Genetics of eukaryotes. Biological and molecular evolution ; Genotype ; Human ; Humans ; Isoenzymes - genetics ; Lung Neoplasms - enzymology ; Lung Neoplasms - epidemiology ; Lung Neoplasms - genetics ; Male ; Medical sciences ; Mixed Function Oxygenases - genetics ; Oligonucleotides - genetics ; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions ; Pharmacology. Drug treatments ; Polymerase Chain Reaction ; Polymorphism, Genetic - genetics ; Population genetics, reproduction patterns ; Smoking - genetics</subject><ispartof>Pharmacogenetics (London), 2001-02, Vol.11 (1), p.39-44</ispartof><rights>2001 INIST-CNRS</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-bb17d86804b601bfe080e0ca93e928ff32e14bdce5c51eb0a6f03d4ba20d60193</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=901125$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11207029$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:1942820$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>LORIOT, Marie-Anne</creatorcontrib><creatorcontrib>REBUISSOU, Sandra</creatorcontrib><creatorcontrib>OSCARSON, Mikael</creatorcontrib><creatorcontrib>CENEE, Sylvie</creatorcontrib><creatorcontrib>MIYAMOTO, Masami</creatorcontrib><creatorcontrib>ARIYOSHI, Noritaka</creatorcontrib><creatorcontrib>KAMATAKI, Tetsuya</creatorcontrib><creatorcontrib>HEMON, Denis</creatorcontrib><creatorcontrib>BEAUNE, Philippe</creatorcontrib><creatorcontrib>STÜCKER, Isabelle</creatorcontrib><title>Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population</title><title>Pharmacogenetics (London)</title><addtitle>Pharmacogenetics</addtitle><description>Cytochrome P450 2A6 (CYP2A6) is involved in the C-oxidation of nicotine and in the metabolic activation of tobacco nitrosamines. Recent data have suggested that CYP2A6 genetic polymorphisms might play a role in tobacco dependence and consumption as well as in lung cancer risk. However, the previously published studies were based on a genotyping method that overestimated the frequencies of deficient alleles, leading to misclassification for the CYP2A6 genotype. In this study, we genotyped DNA from 244 lung cancer patients and from 250 control subjects for CYP2A6 (wild-type allele CYP2A6*1, and two deficient alleles: CYP2A6*2, and CYP2A6*4, the latter corresponding to a deletion of the gene) using a more specific procedure. In this Caucasian population, we found neither a relation between genetically impaired nicotine metabolism and cigarette consumption, nor any modification of lung cancer risk related to the presence of defective CYP2A6 alleles (odds ratio = 1.1, 95% confidence interval = 0.7-1.9).</description><subject>Aryl Hydrocarbon Hydroxylases</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Cytochrome P-450 CYP2A6</subject><subject>Cytochrome P-450 Enzyme System - genetics</subject><subject>DNA Ligases - genetics</subject><subject>France - epidemiology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>General pharmacology</subject><subject>Genetic Predisposition to Disease</subject><subject>Genetics of eukaryotes. Biological and molecular evolution</subject><subject>Genotype</subject><subject>Human</subject><subject>Humans</subject><subject>Isoenzymes - genetics</subject><subject>Lung Neoplasms - enzymology</subject><subject>Lung Neoplasms - epidemiology</subject><subject>Lung Neoplasms - genetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mixed Function Oxygenases - genetics</subject><subject>Oligonucleotides - genetics</subject><subject>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymerase Chain Reaction</subject><subject>Polymorphism, Genetic - genetics</subject><subject>Population genetics, reproduction patterns</subject><subject>Smoking - genetics</subject><issn>0960-314X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo90E1PxCAQBmAOGtevv2BITLxVByhtOZqNX8kmetDEWwN06nZtoUIbs_9ezK5yADLzzHsYQiiDawaqvIF0KlmyjAMwSBdkvyV5QI5BFZAJlr8vyEmMm9SXQvAjsmCMQwlcHZPNAzqcOktH328HH8Z1F4dIfUvtdvJ2HfyA9CWXQPltQTtHNbU6Yma9m4LvaZzmZku9o_3sPlLLWQw7dh_Q2XXKHedeT513Z-Sw1X3E8_17St7u716Xj9nq-eFpebvKbJ4XU2YMK5uqqCA3BTDTIlSAYLUSqHjVtoIjy01jUVrJ0IAuWhBNbjSHJg0ocUqyXW78xnE29Ri6QYdt7XVX70uf6Ye1VAqgTP5q58fgv2aMUz100WLfa4d-jnUJsuS5KBK82MPZDNj8B_9tM4HLPdDR6r4NaR1d_HcKkpTiB-uQg0Y</recordid><startdate>20010201</startdate><enddate>20010201</enddate><creator>LORIOT, Marie-Anne</creator><creator>REBUISSOU, Sandra</creator><creator>OSCARSON, Mikael</creator><creator>CENEE, Sylvie</creator><creator>MIYAMOTO, Masami</creator><creator>ARIYOSHI, Noritaka</creator><creator>KAMATAKI, Tetsuya</creator><creator>HEMON, Denis</creator><creator>BEAUNE, Philippe</creator><creator>STÜCKER, Isabelle</creator><general>Lippincott Williams and Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>20010201</creationdate><title>Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population</title><author>LORIOT, Marie-Anne ; REBUISSOU, Sandra ; OSCARSON, Mikael ; CENEE, Sylvie ; MIYAMOTO, Masami ; ARIYOSHI, Noritaka ; KAMATAKI, Tetsuya ; HEMON, Denis ; BEAUNE, Philippe ; STÜCKER, Isabelle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-bb17d86804b601bfe080e0ca93e928ff32e14bdce5c51eb0a6f03d4ba20d60193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Aryl Hydrocarbon Hydroxylases</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Cytochrome P-450 CYP2A6</topic><topic>Cytochrome P-450 Enzyme System - genetics</topic><topic>DNA Ligases - genetics</topic><topic>France - epidemiology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>General pharmacology</topic><topic>Genetic Predisposition to Disease</topic><topic>Genetics of eukaryotes. Biological and molecular evolution</topic><topic>Genotype</topic><topic>Human</topic><topic>Humans</topic><topic>Isoenzymes - genetics</topic><topic>Lung Neoplasms - enzymology</topic><topic>Lung Neoplasms - epidemiology</topic><topic>Lung Neoplasms - genetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mixed Function Oxygenases - genetics</topic><topic>Oligonucleotides - genetics</topic><topic>Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymerase Chain Reaction</topic><topic>Polymorphism, Genetic - genetics</topic><topic>Population genetics, reproduction patterns</topic><topic>Smoking - genetics</topic><toplevel>online_resources</toplevel><creatorcontrib>LORIOT, Marie-Anne</creatorcontrib><creatorcontrib>REBUISSOU, Sandra</creatorcontrib><creatorcontrib>OSCARSON, Mikael</creatorcontrib><creatorcontrib>CENEE, Sylvie</creatorcontrib><creatorcontrib>MIYAMOTO, Masami</creatorcontrib><creatorcontrib>ARIYOSHI, Noritaka</creatorcontrib><creatorcontrib>KAMATAKI, Tetsuya</creatorcontrib><creatorcontrib>HEMON, Denis</creatorcontrib><creatorcontrib>BEAUNE, Philippe</creatorcontrib><creatorcontrib>STÜCKER, Isabelle</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Pharmacogenetics (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LORIOT, Marie-Anne</au><au>REBUISSOU, Sandra</au><au>OSCARSON, Mikael</au><au>CENEE, Sylvie</au><au>MIYAMOTO, Masami</au><au>ARIYOSHI, Noritaka</au><au>KAMATAKI, Tetsuya</au><au>HEMON, Denis</au><au>BEAUNE, Philippe</au><au>STÜCKER, Isabelle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population</atitle><jtitle>Pharmacogenetics (London)</jtitle><addtitle>Pharmacogenetics</addtitle><date>2001-02-01</date><risdate>2001</risdate><volume>11</volume><issue>1</issue><spage>39</spage><epage>44</epage><pages>39-44</pages><issn>0960-314X</issn><abstract>Cytochrome P450 2A6 (CYP2A6) is involved in the C-oxidation of nicotine and in the metabolic activation of tobacco nitrosamines. Recent data have suggested that CYP2A6 genetic polymorphisms might play a role in tobacco dependence and consumption as well as in lung cancer risk. However, the previously published studies were based on a genotyping method that overestimated the frequencies of deficient alleles, leading to misclassification for the CYP2A6 genotype. In this study, we genotyped DNA from 244 lung cancer patients and from 250 control subjects for CYP2A6 (wild-type allele CYP2A6*1, and two deficient alleles: CYP2A6*2, and CYP2A6*4, the latter corresponding to a deletion of the gene) using a more specific procedure. In this Caucasian population, we found neither a relation between genetically impaired nicotine metabolism and cigarette consumption, nor any modification of lung cancer risk related to the presence of defective CYP2A6 alleles (odds ratio = 1.1, 95% confidence interval = 0.7-1.9).</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams and Wilkins</pub><pmid>11207029</pmid><doi>10.1097/00008571-200102000-00005</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0960-314X |
| ispartof | Pharmacogenetics (London), 2001-02, Vol.11 (1), p.39-44 |
| issn | 0960-314X |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_599007 |
| source | Journals@Ovid Ovid Autoload; MEDLINE |
| subjects | Aryl Hydrocarbon Hydroxylases Biological and medical sciences Case-Control Studies Cytochrome P-450 CYP2A6 Cytochrome P-450 Enzyme System - genetics DNA Ligases - genetics France - epidemiology Fundamental and applied biological sciences. Psychology General pharmacology Genetic Predisposition to Disease Genetics of eukaryotes. Biological and molecular evolution Genotype Human Humans Isoenzymes - genetics Lung Neoplasms - enzymology Lung Neoplasms - epidemiology Lung Neoplasms - genetics Male Medical sciences Mixed Function Oxygenases - genetics Oligonucleotides - genetics Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions Pharmacology. Drug treatments Polymerase Chain Reaction Polymorphism, Genetic - genetics Population genetics, reproduction patterns Smoking - genetics |
| title | Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T12%3A53%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Genetic%20polymorphisms%20of%20cytochrome%20P450%202A6%20in%20a%20case-control%20study%20on%20lung%20cancer%20in%20a%20French%20population&rft.jtitle=Pharmacogenetics%20(London)&rft.au=LORIOT,%20Marie-Anne&rft.date=2001-02-01&rft.volume=11&rft.issue=1&rft.spage=39&rft.epage=44&rft.pages=39-44&rft.issn=0960-314X&rft_id=info:doi/10.1097/00008571-200102000-00005&rft_dat=%3Cproquest_swepu%3E70572436%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70572436&rft_id=info:pmid/11207029&rfr_iscdi=true |